HIGHLIGHTS
- who: Zi-Han Zhang from the Military Command, China University of Chinese Academy of have published the paper: Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis, in the Journal: (JOURNAL)
- what: A This study demonstrated that interventional therapy (125I seed strand and PVS implantation plus TACE) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) is a safe and effective treatment strategy for HCC patients with Vp4 PVTT. The main reason for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.